Clinical trials: Conn Syndrome
Hypertension, Primary Aldosteronism
Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat
The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy.
- Conditions
- Hypertension, Primary Aldosteronism, Hypokalemia
- Trial name
- SSTT (NCT06569589)
- Testing
- 23NaMRI Scan, Potassium Chloride (KCl)
- Where
- 4 sites in Singapore
- Volunteers
- 80 people
- Sponsor
- Jens Titze
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
10% of patients with hypertension potentially have the treatable condition - primary aldosteronism (PA). This is caused by either bilateral adrenal disease (~40%), managed with lifelong medications; or unilateral disease (~60%)…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Adrenal Tumors
- Trial name
- NCT06100367
- Testing
- 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
- Where
- 7 sites in Singapore
- Volunteers
- 97 people
- Sponsor
- Changi General Hospital
Primary Aldosteronism
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.
The objective of this observational study is to utilize the advantages of 68Ga-Pentixafor subtyping diagnosis and the diagnostic ability of 68Ga-FAPI-04 for cardiovascular disease to identify primary aldosterone patients in need…
- Trial name
- NCT06756737
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai East Hospital
Hyperaldosteronism, Renal Insufficiency
The Water Intake Trail and Primary Aldosteronism Postoperation(WIT-PAP)
To investigate whether increasing water intake has renal protective effect on PA patients after surgical treatment.
- Trial name
- NCT04150666
- Testing
- Hydration
- Where
- China
- Sponsor
- Qifu Li
Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Calcium Channel Blockade in Primary Aldosteronism
This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.
- Trial name
- CCB-PA (NCT04179019)
- Testing
- Amlodipine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Primary Hyperaldosteronism
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.
- Trial name
- NCT00732771
- Testing
- LCI699
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Novartis
Primary Aldosteronism
The Effect of Disease-specific Treatment on Bone Turnover Markers in Patients With Primary Aldosteronism
Primary aldosteronism (PA) is a disorder of the adrenal gland causing an autonomous overproduction of mineralocorticoids, leading to arterial hypertension. Although rare, it is the most frequent cause of secondary hypertension.
- Trial name
- NCT02216721
- Where
- Malaysia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University Malaysia Sarawak
Primary Aldosteronism Due to Conn Adenoma, Radiofrequency Ablation Treatment
Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension
Primary aldosteronism (PA) is characterized by hypertension, frequent hypokalaemia, and an inappropriately high aldosterone-to-renin ratio (ARR).
- Conditions
- Primary Aldosteronism Due to Conn Adenoma, Radiofrequency Ablation Treatment, Adrenalectomy
- Trial name
- ADERADHTA2 (NCT07470580)
- Testing
- RFA -radiofrequency ablation, Adrenalectomy
- Where
- France
- Volunteers
- 134 people
- Sponsor
- University Hospital, Toulouse
Cushing Syndrome, Pheochromocytoma
Metabolic Myopathy in Endocrinopathy
Endocrine diseases including Cushing's syndrome and phaeochromocytoma/paraganglioma (PPGL) but not Conn's syndrome are associated with muscle wasting and weakness.
- Conditions
- Cushing Syndrome, Pheochromocytoma, Conns Syndrome, Metabolic Myopathy
- Trial name
- LYDIA (NCT05456997)
- Testing
- Muscle biopsy
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Barts & The London NHS Trust